Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
PLoS One ; 16(6): e0251783, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-34111131

RESUMEN

In this work, we aimed to develop an automatic algorithm for the quantification of total volume and lung impairments in four different diseases. The quantification was completely automatic based upon high resolution computed tomography exams. The algorithm was capable of measuring volume and differentiating pulmonary involvement including inflammatory process and fibrosis, emphysema, and ground-glass opacities. The algorithm classifies the percentage of each pulmonary involvement when compared to the entire lung volume. Our algorithm was applied to four different patients groups: no lung disease patients, patients diagnosed with SARS-CoV-2, patients with chronic obstructive pulmonary disease, and patients with paracoccidioidomycosis. The quantification results were compared with a semi-automatic algorithm previously validated. Results confirmed that the automatic approach has a good agreement with the semi-automatic. Bland-Altman (B&A) demonstrated a low dispersion when comparing total lung volume, and also when comparing each lung impairment individually. Linear regression adjustment achieved an R value of 0.81 when comparing total lung volume between both methods. Our approach provides a reliable quantification process for physicians, thus impairments measurements contributes to support prognostic decisions in important lung diseases including the infection of SARS-CoV-2.


Asunto(s)
Algoritmos , COVID-19/diagnóstico por imagen , Pulmón/diagnóstico por imagen , Paracoccidioidomicosis/diagnóstico por imagen , Enfermedad Pulmonar Obstructiva Crónica/diagnóstico por imagen , Tomografía Computarizada por Rayos X , Adulto , Anciano , COVID-19/fisiopatología , Femenino , Humanos , Pulmón/fisiopatología , Mediciones del Volumen Pulmonar/métodos , Masculino , Persona de Mediana Edad , Paracoccidioides/aislamiento & purificación , Paracoccidioidomicosis/fisiopatología , Enfermedad Pulmonar Obstructiva Crónica/fisiopatología , SARS-CoV-2/aislamiento & purificación , Tomografía Computarizada por Rayos X/métodos
2.
Autoimmun Rev ; 20(5): 102801, 2021 May.
Artículo en Inglés | MEDLINE | ID: mdl-33727154

RESUMEN

Multiple sclerosis (MS) is a chronic, immune-mediated, neurodegenerative disorder of the central nervous system (CNS).While the clinical symptoms of MS most commonly manifest between 20 and 40 years of age, approximately 3 to 10% of all MS patients report that their first inaugural events can occur earlier in life, even in childhood, and thus include the pediatric population. The prevalence of MS onset in childhood/adolescence varies between 2.0% and 4.0% of all MS cases according to several extensive studies. The main imaging patterns of pediatric inflammatory demyelinating disorders and mimicking entities, including multiple sclerosis, neuromyelitis optica spectrum disorders, acute disseminated encephalomyelitis, MOG (myelin oligodendrocyte glycoprotein) antibody-related disorders and differential diagnoses will be addressed in this article, highlighting key points to the differential diagnosis.


Asunto(s)
Encefalomielitis Aguda Diseminada , Neuromielitis Óptica , Adolescente , Autoanticuerpos , Niño , Encefalomielitis Aguda Diseminada/diagnóstico , Humanos , Imagen por Resonancia Magnética , Glicoproteína Mielina-Oligodendrócito , Neuromielitis Óptica/diagnóstico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA